GS-9620

DRUG2 trials

Sponsors

Gilead Sciences, Aelix Therapeutics

Conditions

Chronic Hepatitis BHIV/AIDS

Phase 2

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

CompletedNCT04364035

Aelix TherapeuticsHIV/AIDS

Start: 2020-02-20End: 2022-12-16Updated: 2023-07-27

Unknown Phase

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

TerminatedNCT02258581

Gilead SciencesChronic Hepatitis B

Start: 2014-12-09End: 2017-08-14Updated: 2017-10-03

Related Papers

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations